Brain-targeted delivery of peptides

Nicholas Bodor, Peter Buchwald

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A major impediment in the development of peptide-based therapeutics is our inability to successfully deliver and maintain them at their intended site of action. The present review will focus on a novel, unique, chemicalenzymatic approach designated as molecular packaging that represents an extension of the redox chemical delivery system (CDS) approach and can provide brain- and retina- targeted delivery of peptides through rational drug design. This has made possible the non-invasive brain delivery of neuropeptides such as Leuenkephalin-, TRH-, and kyotorphin-analogs in pharmacologically significant and therapeutically effective amounts.

Original languageEnglish
Pages (from-to)100-104
Number of pages5
JournalAmerican Pharmaceutical Review
Volume9
Issue number1
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

kyotorphin
Peptides
Drug Design
Brain
Product Packaging
Neuropeptides
Oxidation-Reduction
Retina
Therapeutics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Brain-targeted delivery of peptides. / Bodor, Nicholas; Buchwald, Peter.

In: American Pharmaceutical Review, Vol. 9, No. 1, 01.01.2006, p. 100-104.

Research output: Contribution to journalArticle

Bodor, Nicholas ; Buchwald, Peter. / Brain-targeted delivery of peptides. In: American Pharmaceutical Review. 2006 ; Vol. 9, No. 1. pp. 100-104.
@article{5273f36cfd874d7080c196a7d75cb495,
title = "Brain-targeted delivery of peptides",
abstract = "A major impediment in the development of peptide-based therapeutics is our inability to successfully deliver and maintain them at their intended site of action. The present review will focus on a novel, unique, chemicalenzymatic approach designated as molecular packaging that represents an extension of the redox chemical delivery system (CDS) approach and can provide brain- and retina- targeted delivery of peptides through rational drug design. This has made possible the non-invasive brain delivery of neuropeptides such as Leuenkephalin-, TRH-, and kyotorphin-analogs in pharmacologically significant and therapeutically effective amounts.",
author = "Nicholas Bodor and Peter Buchwald",
year = "2006",
month = "1",
day = "1",
language = "English",
volume = "9",
pages = "100--104",
journal = "American Pharmaceutical Review",
issn = "1099-8012",
publisher = "Russell Publishing LLC",
number = "1",

}

TY - JOUR

T1 - Brain-targeted delivery of peptides

AU - Bodor, Nicholas

AU - Buchwald, Peter

PY - 2006/1/1

Y1 - 2006/1/1

N2 - A major impediment in the development of peptide-based therapeutics is our inability to successfully deliver and maintain them at their intended site of action. The present review will focus on a novel, unique, chemicalenzymatic approach designated as molecular packaging that represents an extension of the redox chemical delivery system (CDS) approach and can provide brain- and retina- targeted delivery of peptides through rational drug design. This has made possible the non-invasive brain delivery of neuropeptides such as Leuenkephalin-, TRH-, and kyotorphin-analogs in pharmacologically significant and therapeutically effective amounts.

AB - A major impediment in the development of peptide-based therapeutics is our inability to successfully deliver and maintain them at their intended site of action. The present review will focus on a novel, unique, chemicalenzymatic approach designated as molecular packaging that represents an extension of the redox chemical delivery system (CDS) approach and can provide brain- and retina- targeted delivery of peptides through rational drug design. This has made possible the non-invasive brain delivery of neuropeptides such as Leuenkephalin-, TRH-, and kyotorphin-analogs in pharmacologically significant and therapeutically effective amounts.

UR - http://www.scopus.com/inward/record.url?scp=55549119287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549119287&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:55549119287

VL - 9

SP - 100

EP - 104

JO - American Pharmaceutical Review

JF - American Pharmaceutical Review

SN - 1099-8012

IS - 1

ER -